A need for speed

Tetsu Maruyama

Very few new drugs to help treat dementia patients have been developed in recent years. Tetsu Maruyama, PhD, Chief Scientific Officer of the Dementia Discovery Fund (DDF) talks to us about why this progress has been so slow, offers some suggestions on the ways in which this could be improved, and discusses the objectives of the DDF. This interview was recorded at the 2017 Alzheimer’s Association International Conference (AAIC) held in London, UK.